NEJM: Nivolumab for adjuvant treatment after radical resection of high-risk muscle invasive urothelial carcinoma

Muscle invasive urinary passage standard treatment for patients with epithelial cancer radical surgery, cancer of the bladder, including bladder or urinary tract tumor resection radical nephrectomy, but more than 50% of the pathological evidence of tumor invasion by intrinsic muscles involves areas or Patients with lymph nodes will have metastatic recurrence after surgery.

Muscle invasive urinary passage standard treatment for patients with epithelial cancer radical surgery, cancer of the bladder, including bladder or urinary tract tumor resection radical nephrectomy, but more than 50% of the pathological evidence of tumor invasion by intrinsic muscles involves areas or Patients with lymph nodes will have metastatic recurrence after surgery.

This study is a phase III , multi-center, double-blind, randomized, controlled trial.

This study is a phase III , multi-center, double-blind, randomized, controlled trial.

353 patients received nivolumab treatment and 356 patients received placebo.

Differences in disease-free survival between all populations and PD-L1 positive populations

Differences in disease-free survival between all populations and PD-L1 positive populations

In patients with high-risk muscle invasive urothelial cancer who have undergone radical surgery, adjuvant nivolumab treatment can significantly prolong the disease-free survival of the patients .

In patients with high-risk muscle invasive urothelial cancer who have undergone radical surgery, adjuvant nivolumab treatment can significantly prolong the disease-free survival of the patients .

Original source:

Dean F.

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.


Leave a message here